Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Marcelo V. Negrao"'
Autor:
Lingzhi Hong, Whitney E. Lewis, Monique Nilsson, Sonia Patel, Susan Varghese, Melvin J. Rivera, Robyn R. Du, Pingjun Chen, Haley N. Kemp, Waree Rinsurongkawong, Simon Heeke, Amy R. Spelman, Yasir Y. Elamin, Marcelo V. Negrao, Boris Sepesi, Don L. Gibbons, J. Jack Lee, Jia Wu, Natalie I. Vokes, John V. Heymach, Jianjun Zhang, Xiuning Le
Publikováno v:
Cancers, Vol 14, Iss 14, p 3473 (2022)
Background: The benefit of chemotherapy combined with immunotherapy in EGFR-mutant lung adenocarcinoma (LUAD) patients whose tumor developed resistance to EGFR tyrosine kinase inhibitors (TKIs) is not thoroughly investigated. The goal of this retrosp
Externí odkaz:
https://doaj.org/article/cf3af3299f96410d8a38947177fd3404
Autor:
Marcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, Katja Schulze, Ilze Bara, Vincent Shen, Hao Xu, Sylvia Hu, Dawen Sui, Yasir Y Elamin, Xiuning Le, Michael E Goldberg, Karthikeyan Murugesan, Chang-Jiun Wu, Jianhua Zhang, David S Barreto, Jacqulyne P Robichaux, Alexandre Reuben, Tina Cascone, Carl M Gay, Kyle G Mitchell, Lingzhi Hong, Waree Rinsurongkawong, Jack A Roth, Stephen G Swisher, Jack Lee, Anne Tsao, Vassiliki Papadimitrakopoulou, Don L Gibbons, Bonnie S Glisson, Gaurav Singal, Vincent A Miller, Brian Alexander, Garrett Frampton, Lee A Albacker, David Shames, Jianjun Zhang, John V Heymach
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundNon-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. We
Autor:
Maria Laura Rubin, Marcelo V. Negrao, Vincent K. Lam, Jack A. Roth, Vassiliki A. Papadimitrakopoulou, Stephen G. Swisher, John V. Heymach, J. Jack Lee, Waree Rinsurongkawong, Ignacio I. Wistuba, Alexandre Reuben, Jeff Lewis, Don L. Gibbons, Jianjun Zhang, Lara Lacerda Landry, Bonnie S. Glisson, George R. Blumenschein, Emily Roarty
Publikováno v:
Journal of Thoracic Oncology. 14:1021-1031
Introduction Immune checkpoint blockade (ICB) has revolutionized the treatment of NSCLC, but only approximately 15% of patients achieve durable benefit. Understanding mechanisms of resistance to ICB is pivotal in developing more effective treatment s
Autor:
John V. Heymach, Boris Sepesi, Alexandre Reuben, Chi-Wan Chow, Ara A. Vaporciyan, Roohussaba Khairullah, Marie Andrée Forget, Ignacio I. Wistuba, Peixin Jiang, Marcelo V. Negrao, Parin Shah, Annika Weissferdt, Anirban Maitra, Junya Fujimoto, Lorenzo Federico, Don L. Gibbons, Tina Cascone, Chantale Bernatchez, Meredith Frank, Cara Haymaker, Jack A. Roth, Jianjun Zhang, Yan Long, Daniel J. McGrail, S.H. Lin, Kyle G. Mitchell
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundWhile immune checkpoint blockade is regarded as standard of care for treatment of non-small cell lung cancer (NSCLC), up to 50% of patients with metastatic NSCLC do not achieve an optimal response.1–3 Previous work by our group and others
Autor:
Lixia Diao, Youhong Fan, Marcelo V. Negrao, David H. Peng, Triparna Sen, John V. Heymach, Vassiliki A. Papadimitrakopoulou, Robert J. Cardnell, Ignacio I. Wistuba, Junya Fujimoto, C. Allison Stewart, Laura A. Gibson, Carminia Maria Della Corte, Bertha Leticia Rodriguez, Carmen Behrens, Jing Wang, Kavya Ramkumar, Jared J. Fradette, Qi Wang, Lauren Averett Byers, Luisa M. Solis Soto, Ferdinandos Skoulidis, Don L. Gibbons
Publikováno v:
J Thorac Oncol
Introduction Although the combination of anti–programmed cell death-1 or anti–programmed cell death ligand-1 (PD-L1) with platinum chemotherapy is a standard of care for NSCLC, clinical responses vary. Even though predictive biomarkers (which inc
Autor:
Carmen Behrens, Chantale Bernatchez, Ara Vaporiciyan, Alexandre Reuben, Edwin R. Parra, Ignacio I. Wistuba, Jianhua Zhang, Emily Roarty, Won-Chul Lee, Don L. Gibbons, Jianjun Zhang, Boris Sepesi, Tatiana Karpinets, Marcelo V. Negrao, Jack A. Roth, Xiuning Le, John V. Heymach, Cara Haymaker, Jun Li
Publikováno v:
Cancer Research. 79:5028-5028
Background: Although immune checkpoint blockade has been successfully utilized in treating patients with non-small cell lung cancer (NSCLC), the benefit of immunotherapy for patients with advanced EGFR-mutant (EGFRm) NSCLC has been limited. Data from